Biomarin Pharmaceutical Inc (BMRN) - Total Assets
Based on the latest financial reports, Biomarin Pharmaceutical Inc (BMRN) holds total assets worth $8.59 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Biomarin Pharmaceutical Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Biomarin Pharmaceutical Inc - Total Assets Trend (1998–2025)
This chart illustrates how Biomarin Pharmaceutical Inc's total assets have evolved over time, based on quarterly financial data. Explore Biomarin Pharmaceutical Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Biomarin Pharmaceutical Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Biomarin Pharmaceutical Inc's total assets of $8.59 Billion consist of 52.1% current assets and 47.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.3% |
| Accounts Receivable | $908.21 Million | 12.0% |
| Inventory | $1.30 Billion | 17.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $213.84 Million | 2.8% |
| Goodwill | $196.20 Million | 2.6% |
Asset Composition Trend (1998–2025)
This chart illustrates how Biomarin Pharmaceutical Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Biomarin Pharmaceutical Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biomarin Pharmaceutical Inc's current assets represent 52.1% of total assets in 2025, an increase from 40.6% in 1998.
- Cash Position: Cash and equivalents constituted 17.3% of total assets in 2025, down from 29.8% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 37.0% in 1998.
- Asset Diversification: The largest asset category is inventory at 17.1% of total assets.
Biomarin Pharmaceutical Inc Competitors by Total Assets
Key competitors of Biomarin Pharmaceutical Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
Biomarin Pharmaceutical Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.81 | 5.52 | 5.32 |
| Quick Ratio | 4.20 | 3.49 | 3.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.81 Billion | $2.84 Billion | $1.91 Billion |
Biomarin Pharmaceutical Inc - Advanced Valuation Insights
This section examines the relationship between Biomarin Pharmaceutical Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.77 |
| Latest Market Cap to Assets Ratio | 1.39 |
| Asset Growth Rate (YoY) | 8.7% |
| Total Assets | $7.59 Billion |
| Market Capitalization | $10.57 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Biomarin Pharmaceutical Inc's assets above their book value (1.39x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Biomarin Pharmaceutical Inc's assets grew by 8.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Biomarin Pharmaceutical Inc (1998–2025)
The table below shows the annual total assets of Biomarin Pharmaceutical Inc from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.59 Billion | +8.66% |
| 2024-12-31 | $6.99 Billion | +2.15% |
| 2023-12-31 | $6.84 Billion | +7.32% |
| 2022-12-31 | $6.38 Billion | +6.19% |
| 2021-12-31 | $6.00 Billion | +2.66% |
| 2020-12-31 | $5.85 Billion | +24.69% |
| 2019-12-31 | $4.69 Billion | +5.94% |
| 2018-12-31 | $4.43 Billion | -4.45% |
| 2017-12-31 | $4.63 Billion | +15.15% |
| 2016-12-31 | $4.02 Billion | +7.89% |
| 2015-12-31 | $3.73 Billion | +49.75% |
| 2014-12-31 | $2.49 Billion | +10.98% |
| 2013-12-31 | $2.24 Billion | +43.08% |
| 2012-12-31 | $1.57 Billion | +20.11% |
| 2011-12-31 | $1.31 Billion | +3.41% |
| 2010-12-31 | $1.26 Billion | +37.67% |
| 2009-12-31 | $917.16 Million | +1.15% |
| 2008-12-31 | $906.70 Million | +11.21% |
| 2007-12-31 | $815.28 Million | +75.92% |
| 2006-12-31 | $463.44 Million | +137.29% |
| 2005-12-31 | $195.30 Million | -16.17% |
| 2004-12-31 | $232.97 Million | -9.12% |
| 2003-12-31 | $256.34 Million | +131.74% |
| 2002-12-31 | $110.62 Million | -35.62% |
| 2001-12-31 | $171.81 Million | +123.33% |
| 2000-12-31 | $76.93 Million | -25.70% |
| 1999-12-31 | $103.55 Million | +228.62% |
| 1998-12-31 | $31.51 Million | -- |
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV t… Read more